Olympus Corporation (TYO:7733)
Japan
· Delayed Price · Currency is JPY 2,027.50
-18.50 (-0.90%)
At close: Dec 5, 2025
Revenue by Geography
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Japan Revenue | 106.84B | 110.11B |
Log In |
Log In |
Log In | Upgrade
|
| North America Revenue | 397.59B | 413.81B |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue | 258.15B | 254.62B |
Log In |
Log In |
Log In | Upgrade
|
| China Revenue | 85.49B | 95.72B |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Post-FY2019 Reporting) | 97.62B | 93.69B |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue (Pre-FY2020 Reporting) | 183.11B | 189.41B |
Log In |
Log In |
Log In | Upgrade
|
| Other Countries Revenue | 31.62B | 28.84B |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Endoscopic Solutions Division Revenue | 636.14B |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Revenue | 360.66B |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Solutions Division Revenue | 996.80B |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Post-FY2024 Reporting) | 530.00M |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Revenue (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
Revenue Breakdown 2
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Gastrointestinal Solutions Division Revenue | 658.66B | 674.04B |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Interventional Solutions Division Revenue | 318.64B | 322.76B |
Log In |
Log In |
Log In | Upgrade
|
EBIT
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Endoscopic Solutions Division Operating Profit | 141.40B |
Log In |
Log In |
Log In | Upgrade
|
| Therapeutic Solutions Division Operating Profit | 61.45B |
Log In |
Log In |
Log In | Upgrade
|
| Total Medical Solutions Division Operating Profit | 202.85B |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Post-FY2024 Reporting) | -473.00M |
Log In |
Log In |
Log In | Upgrade
|
| Other Division Operating Profit (Pre-FY2025 Reporting) | - |
Log In |
Log In |
Log In | Upgrade
|
| Eliminations from Division Operating Profit | -39.92B |
Log In |
Log In |
Log In | Upgrade
|
EBIT 2
Fiscal year is April - March.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| Gastrointestinal Solutions Division Operating Profit | 143.72B | 167.89B |
Log In |
Log In |
Log In | Upgrade
|
| Surgical & Interventional Solutions Division Operating Profit | 8.24B | 14.69B |
Log In |
Log In |
Log In | Upgrade
|
Key Performance Indicators
Fiscal year is April - March.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | 2013 - 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | 2013 - 2020 |
| ESD - GI Endoscopy Revenue Growth Rate After FX Adjustment | 3.00% |
Log In |
Log In |
Log In | Upgrade
|
| ESD - Surgical Endoscopy Revenue Growth Rate After FX Adjustment | 5.00% |
Log In |
Log In |
Log In | Upgrade
|
| ESD - Medical Service Revenue Growth Rate After FX Adjustment | 5.00% |
Log In |
Log In |
Log In | Upgrade
|
| Total Endoscopic Solutions Division (ESD) Revenue Growth Rate After FX Adjustment | 4.00% |
Log In |
Log In |
Log In | Upgrade
|
| TSD - GI EndoTherapy Revenue Growth Rate After FX Adjustment | 2.00% |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Urology Revenue Growth Rate After FX Adjustment | 6.00% |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Respiratory Revenue Growth Rate After FX Adjustment | 10.00% |
Log In |
Log In |
Log In | Upgrade
|
| TSD - Other Therapeutic Areas Revenue Growth Rate After FX Adjustment | -7.00% |
Log In |
Log In |
Log In | Upgrade
|
| Total Therapeutic Solutions Division (TSD) Revenue Growth Rate After FX Adjustment | 3.00% |
Log In |
Log In |
Log In | Upgrade
|
| Company's Total Revenue Growth Rate After FX Adjustment | - |
Log In |
Log In |
Log In | Upgrade
|